摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

triamcinolone acetonide | 3092-61-3

中文名称
——
中文别名
——
英文名称
triamcinolone acetonide
英文别名
Triamcinolone acetonide hemisuccinate;4-[2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethoxy]-4-oxobutanoic acid
triamcinolone acetonide化学式
CAS
3092-61-3
化学式
C28H35FO9
mdl
——
分子量
534.579
InChiKey
GWKQSBXDFHODNU-UQPSFNCESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    38
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    136
  • 氢给体数:
    2
  • 氢受体数:
    10

SDS

SDS:dcf2dc6cfcce88222f087c256331e141
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(4-羟基-苯基)-[1,2]二硫醇-3-硫酮triamcinolone acetonide4-二甲氨基吡啶盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 四氢呋喃 为溶剂, 反应 12.17h, 以59%的产率得到1-O-[2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 4-O-[4-(5-sulfanylidenedithiol-3-yl)phenyl] butanedioate
    参考文献:
    名称:
    Hybrids between H2S-donors and betamethasone 17-valerate or triamcinolone acetonide inhibit mast cell degranulation and promote hyperpolarization of bronchial smooth muscle cells
    摘要:
    DOI:
    10.1016/j.ejmech.2021.113517
  • 作为产物:
    描述:
    丁二酸酐曲安奈德吡啶4-二甲氨基吡啶 作用下, 以93%的产率得到triamcinolone acetonide
    参考文献:
    名称:
    Hybrids between H2S-donors and betamethasone 17-valerate or triamcinolone acetonide inhibit mast cell degranulation and promote hyperpolarization of bronchial smooth muscle cells
    摘要:
    DOI:
    10.1016/j.ejmech.2021.113517
点击查看最新优质反应信息

文献信息

  • ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF
    申请人:Aerie Pharmaceuticals, Inc.
    公开号:US20200071275A1
    公开(公告)日:2020-03-05
    Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
    本文提供了一些化合物和制药组合物,可用于调节激酶活性及相关疾病。本文还提供了一种治疗主题眼疾或疾病的方法。本文还提供了一种降低主题眼内压的方法。本文还提供了一种在细胞中调节激酶活性的方法。本文还提供了制备本文提供的化合物的方法,以及制备本文提供的化合物所需的化合物。
  • Drug-Protein Conjugates: Preparation of Triamcinolone-Acetonide Containing Bovine Serum Albumin/Keyhole Limpet Hemocyanin-Conjugates and Polyclonal Antibodies
    作者:Franz Gabor、Fritz Pittner、Paul Spiegl
    DOI:10.1002/ardp.19953281109
    日期:——
    hapten was conjugated to the carrier‐protein bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) by different amide‐bond generating methods (imidazolide‐, carbodiimide‐, carbodiimide/sulfo‐N‐hydroxysuccinimde‐, mixed anhydride‐method) yielding antigens of quite different conjugation number, solubility and usefulness. The mixed anhydride‐method yielded most useful soluble conjugates bearing 0
    已经开发了一种放射免疫测定法,用于在皮克水平对曲安奈德 (TAAc) 进行定量。为了使用 TAAc 作为抗原表位,首先将药物在 C-21 位半琥珀酰化,如衍生化后的 13C-NMR-和质谱证实。该半抗原通过不同的酰胺键生成方法(咪唑啉-、碳二亚胺-、碳二亚胺/磺基-N-羟基琥珀酰亚胺-、混合酸酐法)与载体蛋白牛血清白蛋白(BSA)或钥孔血蓝蛋白(KLH)结合,得到结合数、溶解度和用途完全不同的抗原。混合酸酐法产生了最有用的可溶性偶联物,每摩尔载体蛋白含有 0.3-31.5 摩尔 TAAc。通过碳二亚胺方法偶联产生不溶性偶联物,由于偶联剂修饰残基的形成和载体蛋白的交联,因此不适用于半抗原免疫测定中的抗原合成。通过分离可溶性半抗原-抗体复合物来评估通过用 TAAc-BSA 和 TAAc-KLH 免疫获得的抗血清的特异性,并开发了 RIA 方案,提供 200 pg (0.46 pmol) TAAc/ml
  • Isoquinoline-steroid conjugates and uses thereof
    申请人:Aerie Pharmaceuticals, Inc.
    公开号:US11059789B2
    公开(公告)日:2021-07-13
    Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
    本文提供了用于调节激酶活性及相关疾病的化合物和药物组合物。本文还提供了治疗受试者眼部疾病或失调的方法。本文还提供了降低受试者眼压的方法。本文还提供了调节细胞中激酶活性的方法。本文还提供了制造本文提供的化合物的方法,以及用于制备本文提供的化合物的化合物。
  • [EN] ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS ISOQUINOLINE-STÉROÏDE ET UTILISATIONS ASSOCIÉES
    申请人:AERIE PHARMACEUTICALS INC
    公开号:WO2020047496A1
    公开(公告)日:2020-03-05
    Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
  • Hybrids between H2S-donors and betamethasone 17-valerate or triamcinolone acetonide inhibit mast cell degranulation and promote hyperpolarization of bronchial smooth muscle cells
    作者:Flavia Giordano、Angela Corvino、Antonia Scognamiglio、Valentina Citi、Era Gorica、Caterina Fattorusso、Marco Persico、Giuseppe Caliendo、Ferdinando Fiorino、Elisa Magli、Elisa Perissutti、Vincenzo Santagada、Beatrice Severino、Rocco Carmelo Pavese、Francesco Petti、Alma Martelli、Vincenzo Calderone、Francesco Frecentese
    DOI:10.1016/j.ejmech.2021.113517
    日期:2021.10
查看更多